A global precision-medicine platform uniting cell therapy, regenerative medicine and longevity science. We don't simply treat disease — we design every healthy moment of your life.
IPMC is a biopharmaceutical company developing new medicines for neurodegenerative and cardiometabolic disease — alongside a cell-therapy, regenerative-medicine and longevity platform spanning the full value chain.
Small-molecule programs led by KDS2010 (Tisolagiline) — a reversible, selective MAO-B inhibitor in Phase 2 for Alzheimer's disease, also in development for obesity.
KDS2010 · Phase 2 →Placental MSC stem-cell therapies that restore damaged nerve, vascular and tissue function — plus commercialization of FDA-cleared amniotic matrix Biovance®.
Biovance® · PDA · PSC →An MFDS-licensed tissue bank and placental/cord-blood biobanking — preserving the stem-cell resources at the very origin of precision and regenerative medicine.
Tissue Bank · LifebankUSA →Genomics- and biomarker-driven personalized care, precision nutrition and disease prediction — extending the human healthspan.
Diagnostics · Nutrition →
Where nature meets advanced medicine — a global bio-destination integrating preventive diagnostics, regenerative therapy and longevity science under one roof.
IPMC's Cell Regenerative Capacity™ (CRC™) measures the activity of individual cells in real time using glutathione (GSH) — a new standard for cell-therapy quality control. From sourcing to therapy, IPMC owns the entire value chain: sourcing, processing, storage and delivery.
IPMC directly operates an MFDS-licensed tissue bank and GMP-grade cell manufacturing. Cleanroom aseptic processing and CRC™ quality control bridge research to clinic and industry.
Through Scilex Bio, a joint venture with Nasdaq-listed Scilex Holding (SCLX), IPMC advances KDS2010 (Tisolagiline) — a novel reversible, selective MAO-B inhibitor for neurodegenerative and cardiometabolic disease. As a representative company of the Bio Innovation Consortium, IPMC holds the exclusive global license to NeuroBiogen's KDS2010.
A highly selective, reversible MAO-B inhibitor that normalizes aberrant astrocytic GABA and H₂O₂ in reactive astrocytes — reducing neuroinflammation and restoring synaptic transmission, learning and memory. It overcomes the limitations seen with irreversible MAO-B inhibitors in long-term use.
Single- and multiple-ascending-dose trials in 88 healthy young and elderly subjects, across Korean and Western populations, showed favorable safety and tolerability with pharmacokinetics suitable for once-daily dosing. KDS2010 is also in development for obesity.
Investigational; not approved by any regulatory authority. Contains forward-looking statements. Source: Scilex Holding Company (GLOBE NEWSWIRE, Dec 11, 2024).
Founded IPMC to make Korea a leader in precision medicine under the vision "From Womb to Heaven," driving an open bio-innovation ecosystem.
Founder of Celularity, Human Longevity and Celgene Cellular Therapeutics — a pioneer of cell therapy who first discovered pluripotent stem cells in the human placenta.
Since the first conference in 2017, IPMC has built a global hub for precision-medicine knowledge. The 2023 IPMCC at KINTEX, Korea gathered ~400 leaders from Korea, the U.S. and China under the theme "Beyond Longevity: Live 120 Like 50™."
Beginning with the first IPMC Conference, we've built a global knowledge hub spanning precision-medicine research, development, clinical application and digital health — convening authorities from industry, medicine, government and academia.
From Times Square and Nasdaq to global summits and the IPMC Conference — a decade of building bridges between science, capital and policy across Korea, the U.S. and beyond.
If you're interested in joint research, technology licensing, investment or partnership, we'd love to connect.
